Riskpilot← Back to searchSign inGet full accessXtherapeutics ApS
APSActiveCVR 37384089Hovmarksvej 73Manufacture of pharmaceutical preparations · NACE 2120Est. 2016— employees
Revenue 2025
DKK 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
DKK 0
+100% vs 2024
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 0 | +100% |
| Total assets | DKK 0 | — |
| Equity | DKK -18K | +0% |
| Employees | — | — |
Legal name
Xtherapeutics ApS
CVR number
37384089
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
20. januar 2016
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen i forening
Company purpose
Selskabets formål er at udvikle og sælge behandlinger til kræft sygdomme og hermed forbundet virksomhed.
Address
Hovmarksvej 73
Phone
+4525374486
Email
cphtla@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 | — | -9 | -17 | -14 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 0 | -7 | 0 | 0 | 0 | -9 | -17 | -14 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -7 | 0 | 0 | 0 | -9 | -17 | -14 | 0 |
| Net financials | 0 | 0 | 0 | 0 | -5 | -5 | -0 | 0 | 0 |
| Profit before tax | 0 | -7 | 0 | 0 | -5 | -14 | -17 | -14 | 0 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 0 | -7 | 0 | 0 | -5 | -14 | -17 | -14 | 0 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 0 | 20 | 14 | 0 | 0 |
| Equity | 0 | -7 | 0 | 0 | -13 | 13 | -4 | -18 | -18 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 8 | 0 | 0 | 13 | 8 | 18 | 18 | 18 |
| Total debt | 0 | 8 | 0 | 0 | 13 | 8 | 18 | 18 | 18 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20172025
Equity ratio
-1843900.0%
This company
38.2%
Market median
-4827063% vs market
20172025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20172025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20172025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20172025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-01-20 – 2017-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TL Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TLA-HOLDING 2010 ApS | Company | 50.0% | 50.0% | 2016 |
| Individual | 20.0% | 20.0% | 2018 | |
| Individual | 20.0% | 20.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TLA-HOLDING 2010 ApS
Xtherapeutics ApS Board members of Xtherapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Lars Andresen | Chief Executive Officer | 0 companies |